1. Home
  2. HWH vs ACXP Comparison

HWH vs ACXP Comparison

Compare HWH & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HWH International Inc.

HWH

HWH International Inc.

HOLD

Current Price

$1.68

Market Cap

9.8M

Sector

Health Care

ML Signal

HOLD

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.57

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HWH
ACXP
Founded
2021
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.8M
8.3M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
HWH
ACXP
Price
$1.68
$1.57
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$95.50
AVG Volume (30 Days)
743.1K
79.1K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
47.37
N/A
EPS
N/A
N/A
Revenue
$866,926.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$0.29
52 Week High
$7.77
$8.34

Technical Indicators

Market Signals
Indicator
HWH
ACXP
Relative Strength Index (RSI) 75.77 34.12
Support Level $1.00 $1.37
Resistance Level $1.85 $2.26
Average True Range (ATR) 0.22 0.11
MACD 0.08 0.00
Stochastic Oscillator 42.50 10.89

Price Performance

Historical Comparison
HWH
ACXP

About HWH HWH International Inc.

HWH International Inc is and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: